Which has stronger valuation & earnings, CNTX or KALA?

Context Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is CNTX or KALA more profitable?

Context Therapeutics' return on equity of -82.06% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% KALA BIO N/A -1,336.10% -94.85%

Does the media prefer CNTX or KALA?

In the previous week, Context Therapeutics had 11 more articles in the media than KALA BIO. MarketBeat recorded 13 mentions for Context Therapeutics and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat Context Therapeutics' score of 0.19 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, INKT or KALA?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is INKT or KALA more profitable?

MiNK Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% KALA BIO N/A -1,336.10% -94.85%

Does the media prefer INKT or KALA?

In the previous week, MiNK Therapeutics had 5 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for MiNK Therapeutics and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat MiNK Therapeutics' score of 0.46 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, INO or KALA?

Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inovio Pharmaceuticals N/A N/A -$84.95M -$1.45 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is INO or KALA more profitable?

Inovio Pharmaceuticals' return on equity of -489.79% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -489.79% -95.40% KALA BIO N/A -1,336.10% -94.85%

Does the media favor INO or KALA?

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than KALA BIO. MarketBeat recorded 5 mentions for Inovio Pharmaceuticals and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat Inovio Pharmaceuticals' score of 0.58 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ATYR or KALA more profitable?

aTyr Pharma's return on equity of -88.95% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -88.95% -65.31% KALA BIO N/A -1,336.10% -94.85%

Does the media prefer ATYR or KALA?

In the previous week, aTyr Pharma had 12 more articles in the media than KALA BIO. MarketBeat recorded 14 mentions for aTyr Pharma and 2 mentions for KALA BIO. aTyr Pharma's average media sentiment score of 0.95 beat KALA BIO's score of 0.93 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, EDSA or KALA?

Edesa Biotech is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edesa Biotech N/A N/A -$7.19M -$1.34 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is EDSA or KALA more profitable?

Edesa Biotech's return on equity of -286.52% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -286.52% -75.36% KALA BIO N/A -1,336.10% -94.85%

Does the media refer more to EDSA or KALA?

In the previous week, Edesa Biotech had 1 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for Edesa Biotech and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat Edesa Biotech's score of 0.93 indicating that KALA BIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KALA BIO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

KALA BIO (KALA) Competitors

$0.88 +0.04 (+4.63%)

As of 04:00 PM Eastern

Compare

KALA vs. CNTX, INKT, INO, ATYR, and EDSA

Should you buy KALA BIO stock or one of its competitors? KALA BIO's main competitors and comparable companies include Context Therapeutics (CNTX), MiNK Therapeutics (INKT), Inovio Pharmaceuticals (INO), aTyr Pharma (ATYR), and Edesa Biotech (EDSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does KALA BIO compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Context Therapeutics' return on equity of -82.06% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
KALA BIO	N/A	-1,336.10%	-94.85%

Context Therapeutics presently has a consensus target price of $6.17, suggesting a potential upside of 1,212.34%. KALA BIO has a consensus target price of $1,158.33, suggesting a potential upside of 130,933.18%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Context Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.26, indicating that its stock price is 326% less volatile than the broader market.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Context Therapeutics had 11 more articles in the media than KALA BIO. MarketBeat recorded 13 mentions for Context Therapeutics and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat Context Therapeutics' score of 0.19 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

Summary

Context Therapeutics beats KALA BIO on 8 of the 13 factors compared between the two stocks.

How does KALA BIO compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

In the previous week, MiNK Therapeutics had 5 more articles in the media than KALA BIO. MarketBeat recorded 7 mentions for MiNK Therapeutics and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat MiNK Therapeutics' score of 0.46 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 2.2% of KALA BIO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

MiNK Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.26, meaning that its stock price is 326% less volatile than the broader market.

MiNK Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
KALA BIO	N/A	-1,336.10%	-94.85%

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 208.10%. KALA BIO has a consensus price target of $1,158.33, suggesting a potential upside of 130,933.18%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MiNK Therapeutics beats KALA BIO on 8 of the 13 factors compared between the two stocks.

How does KALA BIO compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Inovio Pharmaceuticals has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.26, indicating that its share price is 326% less volatile than the broader market.

Inovio Pharmaceuticals' return on equity of -489.79% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%
KALA BIO	N/A	-1,336.10%	-94.85%

26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	N/A	N/A	-$84.95M	-$1.45	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than KALA BIO. MarketBeat recorded 5 mentions for Inovio Pharmaceuticals and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat Inovio Pharmaceuticals' score of 0.58 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inovio Pharmaceuticals presently has a consensus target price of $3.25, indicating a potential upside of 322.08%. KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 130,933.18%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Inovio Pharmaceuticals beats KALA BIO on 7 of the 13 factors compared between the two stocks.

How does KALA BIO compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

aTyr Pharma presently has a consensus target price of $17.00, indicating a potential upside of 3,046.40%. KALA BIO has a consensus target price of $1,158.33, indicating a potential upside of 130,933.18%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

aTyr Pharma has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.26, indicating that its stock price is 326% less volatile than the broader market.

In the previous week, aTyr Pharma had 12 more articles in the media than KALA BIO. MarketBeat recorded 14 mentions for aTyr Pharma and 2 mentions for KALA BIO. aTyr Pharma's average media sentiment score of 0.95 beat KALA BIO's score of 0.93 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

KALA BIO has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	278.93	-$74.12M	-$0.62	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

aTyr Pharma's return on equity of -88.95% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-88.95%	-65.31%
KALA BIO	N/A	-1,336.10%	-94.85%

Summary

aTyr Pharma beats KALA BIO on 11 of the 14 factors compared between the two stocks.

How does KALA BIO compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and KALA BIO (NASDAQ:KALA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

Edesa Biotech's return on equity of -286.52% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-286.52%	-75.36%
KALA BIO	N/A	-1,336.10%	-94.85%

Edesa Biotech is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

In the previous week, Edesa Biotech had 1 more articles in the media than KALA BIO. MarketBeat recorded 3 mentions for Edesa Biotech and 2 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.93 beat Edesa Biotech's score of 0.93 indicating that KALA BIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
KALA BIO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edesa Biotech has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.26, indicating that its share price is 326% less volatile than the broader market.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 24.6% of KALA BIO shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Edesa Biotech currently has a consensus price target of $5.00, suggesting a potential downside of 5.66%. KALA BIO has a consensus price target of $1,158.33, suggesting a potential upside of 130,933.18%. Given KALA BIO's higher possible upside, analysts clearly believe KALA BIO is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Edesa Biotech beats KALA BIO on 9 of the 13 factors compared between the two stocks.

Get KALA BIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KALA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KALA vs. The Competition

Export

Metric	KALA BIO	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$17.10M	$3.73B	$7.04B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.34%
P/E Ratio	-0.01	10.41	268.83	25.29
Price / Sales	N/A	1,273.49	588.87	77.73
Price / Cash	N/A	102.54	72.26	50.42
Price / Book	0.07	17.90	13.16	6.23
Net Income	-$26.98M	-$13.23M	$3.45B	$347.40M
7 Day Performance	26.11%	3.55%	2.02%	1.46%
1 Month Performance	-24.77%	-0.71%	-0.23%	-0.49%
1 Year Performance	-99.76%	60.44%	70.60%	20.91%

KALA BIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KALA KALA BIO	2.3355 of 5 stars	$0.88 +4.6%	$1,158.33 +130,933.2%	-99.8%	$17.10M	N/A	N/A	30	Gap Up
CNTX Context Therapeutics	2.883 of 5 stars	$0.69 +11.5%	$6.17 +789.9%	-31.2%	$57.13M	N/A	N/A	7	Earnings Report Analyst Revision Gap Up
INKT MiNK Therapeutics	3.194 of 5 stars	$11.70 +5.7%	$35.00 +199.1%	-8.1%	$55.15M	N/A	N/A	30	Upcoming Earnings
INO Inovio Pharmaceuticals	2.3335 of 5 stars	$0.68 +2.1%	$3.25 +380.1%	-46.8%	$54.56M	$60K	N/A	320	Earnings Report
ATYR aTyr Pharma	3.1615 of 5 stars	$0.53 0.0%	$17.00 +3,113.6%	-90.5%	$51.89M	$190K	N/A	53	News Coverage Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KALA) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

KALA BIO (KALA) Competitors

KALA vs. CNTX, INKT, INO, ATYR, and EDSA

How does KALA BIO compare to Context Therapeutics?

Summary

How does KALA BIO compare to MiNK Therapeutics?

Summary

How does KALA BIO compare to Inovio Pharmaceuticals?

Summary

How does KALA BIO compare to aTyr Pharma?

Summary

How does KALA BIO compare to Edesa Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

KALA BIO (KALA) Competitors

KALA vs. CNTX, INKT, INO, ATYR, and EDSA

How does KALA BIO compare to Context Therapeutics?

Is CNTX or KALA more profitable?

Do analysts rate CNTX or KALA?

Which has more volatility & risk, CNTX or KALA?

Do insiders & institutionals hold more shares of CNTX or KALA?

Does the media prefer CNTX or KALA?

Which has stronger valuation & earnings, CNTX or KALA?

Summary

How does KALA BIO compare to MiNK Therapeutics?

Does the media prefer INKT or KALA?

Do insiders and institutionals have more ownership in INKT or KALA?

Which has better earnings & valuation, INKT or KALA?

Which has more risk and volatility, INKT or KALA?

Is INKT or KALA more profitable?

Do analysts recommend INKT or KALA?

Summary

How does KALA BIO compare to Inovio Pharmaceuticals?

Which has more volatility & risk, INO or KALA?

Is INO or KALA more profitable?

Do institutionals and insiders have more ownership in INO or KALA?

Which has preferable earnings and valuation, INO or KALA?

Does the media favor INO or KALA?

Do analysts recommend INO or KALA?

Summary

How does KALA BIO compare to aTyr Pharma?

Do insiders and institutionals believe in ATYR or KALA?

Do analysts prefer ATYR or KALA?

Which has more risk & volatility, ATYR or KALA?

Does the media prefer ATYR or KALA?

Which has preferable valuation and earnings, ATYR or KALA?

Is ATYR or KALA more profitable?

Summary

How does KALA BIO compare to Edesa Biotech?

Is EDSA or KALA more profitable?

Which has higher valuation and earnings, EDSA or KALA?

Does the media refer more to EDSA or KALA?

Which has more volatility & risk, EDSA or KALA?

Do institutionals and insiders have more ownership in EDSA or KALA?

Do analysts prefer EDSA or KALA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALA vs. The Competition

KALA BIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools